Alkermes PLC (NASDAQ:ALKS) Director Paul J. Mitchell sold 1,000 shares of the stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $51.98, for a total value of $51,980.00. Following the completion of the sale, the director now owns 9,000 shares in the company, valued at $467,820. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Alkermes PLC (NASDAQ ALKS) opened at $53.70 on Monday. Alkermes PLC has a fifty-two week low of $46.42 and a fifty-two week high of $63.40. The company has a quick ratio of 2.72, a current ratio of 3.05 and a debt-to-equity ratio of 0.23.
Alkermes (NASDAQ:ALKS) last released its quarterly earnings data on Thursday, October 26th. The company reported $0.03 EPS for the quarter, topping the consensus estimate of ($0.01) by $0.04. The company had revenue of $217.40 million for the quarter, compared to the consensus estimate of $231.29 million. Alkermes had a negative return on equity of 7.27% and a negative net margin of 20.12%. Alkermes’s quarterly revenue was up 20.6% on a year-over-year basis. During the same period last year, the business posted ($0.09) EPS. equities analysts predict that Alkermes PLC will post -0.59 earnings per share for the current year.
Several brokerages have recently weighed in on ALKS. ValuEngine upgraded Alkermes from a “sell” rating to a “hold” rating in a report on Friday. BidaskClub downgraded Alkermes from a “sell” rating to a “strong sell” rating in a report on Wednesday, August 9th. Credit Suisse Group set a $66.00 price target on Alkermes and gave the stock a “buy” rating in a report on Tuesday, November 28th. Barclays downgraded Alkermes from an “overweight” rating to an “equal weight” rating and reduced their price target for the stock from $66.00 to $50.00 in a report on Monday, October 16th. Finally, J P Morgan Chase & Co set a $78.00 price target on Alkermes and gave the stock a “buy” rating in a report on Friday, October 27th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and five have issued a buy rating to the stock. Alkermes currently has an average rating of “Hold” and a consensus price target of $63.55.
COPYRIGHT VIOLATION NOTICE: This piece was originally published by Week Herald and is owned by of Week Herald. If you are viewing this piece on another website, it was stolen and republished in violation of United States and international trademark and copyright law. The legal version of this piece can be accessed at https://weekherald.com/2017/12/04/insider-selling-alkermes-plc-alks-director-sells-51980-00-in-stock.html.
Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).
Receive News & Ratings for Alkermes PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes PLC and related companies with MarketBeat.com's FREE daily email newsletter.